SV

Street Verdict

Analyst Scorecard

SHILPAMED · NSE

Shilpa Medicare Limited

₹849.15

-5.72% (-₹51.55)

Prev. close

₹900.7

Volume

15,38,885

Delivery %

46.1%

As of

20 Nov 2026

Price history

₹849.15+₹39.35 (+4.86%) · 3M
18 Aug 2026 → 20 Nov 2026
8509009501,0001,05018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

none in range

Long-Horizon

1 · 1 bull / 0 neutral / 0 bear

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Long-Horizon calls · 1yr+ horizon · verdict pending

CallAnalystInstrumentVerdictActions

Fundamentals

About Shilpa Medicare Limited

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Vishnukant Chaturbhuj Bhutada B. Pharm

Headquarters

Raichur

Employees

1,241

Key stats

Market cap

₹18,210.62 Cr

P/E ratio (TTM)

65.8

Dividend yield

0.06%

EPS (TTM)

₹14.16

Beta (1Y · daily vs NIFTY 50)

0.81

Beta (5Y · monthly vs NIFTY 50)

0.41

Shares float

9.57 Cr

EPS · quarter ended Jun 2026

₹5.16

Financial Performance

01 · Financials

-1000 Cr0 Cr1000 Cr2000 Cr₹-20%0%20%40%FY21FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

Net income the series has no figure for is taken from the company's own statements — FY22: profit attributable to owners.

02 · Earnings Per Share (EPS)

051015₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0001₹-100%-50%0%50%16 Mar 2020 Sept 2119 Sept 2217 Sept 2504 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-20%0%20%40%FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.2×0.4×0.6×FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY22FY24FY25FY26
₹1,159.77 Cr₹1,159.77 Cr₹1,309.76 Cr₹1,548.71 Cr
₹1,062.63 Cr₹1,106.79 Cr₹1,155.58 Cr₹1,282.68 Cr
Profit before share of profit/(loss) of an associates/a joint
₹97.13 Cr₹52.99 Cr₹154.18 Cr₹266.03 Cr
Share of profit / (loss) of an associate/joint venture, net of tax
₹-3.66 Cr₹-4.78 Cr₹-1.27 Cr₹17.12 Cr
Profit/(loss) before exceptional items and tax
₹93.47 Cr₹48.21 Cr₹152.91 Cr₹283.15 Cr
Exceptional Items- (Income) / Expense
₹8.79 Cr₹-6.13 Cr₹30.58 Cr₹-12.16 Cr
Profit before tax
₹102.26 Cr₹54.34 Cr₹122.33 Cr₹295.31 Cr
₹41.68 Cr₹22.39 Cr₹44.04 Cr₹51.99 Cr
₹59.22 Cr₹29.58 Cr₹75.99 Cr₹247.19 Cr
Profit for the year
₹60.58 Cr₹31.96 Cr₹78.29 Cr₹243.33 Cr
₹-1.36 Cr₹-2.37 Cr₹-2.30 Cr₹3.87 Cr
a) Owners of the Company
₹60.66 Cr₹31.87 Cr₹78.29 Cr₹243.33 Cr
b) Non Controlling Interest*
₹-8.02 L₹8.09 L——
a) Owners of the Company
₹-1.36 Cr₹-2.37 Cr₹-2.30 Cr₹3.87 Cr
a) Owners of the Company
₹59.30 Cr₹29.50 Cr₹75.99 Cr₹247.19 Cr
b) Non Controlling Interest*
₹-8.02 L₹8.09 L——
Basic (Rs
7.263.674.0212.44
Diluted (Rs)
7.263.674.0212.44

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹2,875.50 Cr₹2,903.93 Cr₹3,093.24 Cr₹3,310.68 Cr₹3,705.61 Cr
₹2,875.50 Cr₹2,903.93 Cr₹3,093.24 Cr₹3,310.68 Cr₹3,705.61 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹211.61 Cr₹109.53 Cr₹275.78 Cr₹317.38 Cr₹437.76 Cr
₹105.13 Cr₹179.92 Cr₹136.67 Cr₹132.27 Cr₹342.18 Cr
₹-285.50 Cr₹-232.61 Cr₹-166.58 Cr₹-199.13 Cr₹-325.92 Cr
₹25.34 Cr₹19.07 Cr₹31.76 Cr₹28.57 Cr₹45.18 Cr
Components of Cash and Cash Equivalents
₹25.34 Cr————
Cash in Hand
₹33.86 L—₹32.62 L——
Balances with banks - on current accounts
₹30.04 Cr—₹22.62 Cr——
Balances with banks - on unpaid dividend accounts
——₹20.99 L——
Deposits with original maturity of less than 03 months
₹3.45 Cr—₹7.28 Cr——
Fixed deposits having maturity less than 12 months and held as margin money
——₹1.33 Cr——
Book overdraft
₹-8.49 Cr—₹-1.02 L——
Total Cash and Cash Equivalents
——₹31.76 Cr——

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Nov 21–Mar 24(11Q)Apr 24–Jun 24(2Q)Sep 24Dec 24–Sep 25(4Q)Dec 25–Jun 26(3Q)
Promoter53.25%50.01%44.39%44.33%44.23%40.13%
Public46.75%49.99%55.61%55.67%55.77%59.87%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Shilpa Medicare Limited₹18,229.20 Cr₹931.165.97.049.4%0.25+19.7%+160.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Index membership

2 indices

SHILPAMED

Shilpa Medicare - 16 microcap stocks surge up to 390% in CY26, emerge as multibaggers

The Economic Times · 4 days ago

SHILPAMED

Shilpa Medicare reports highest ever revenue and EBITDA in Q2 FY27

Shilpa Medicare Limited posted record Q2 FY27 revenue of INR 538 crore, a 35% year‑on‑year rise, and EBITDA of INR 151 crore, up 37% YoY, driven by growth in its API, CDMO, formulation and biologics segments. The half‑year results showed INR 1,007 crore revenue and a 29% EBITDA margin, indicating the company is moving from investment to profit‑generation phases.

12 days ago·Read at InvestyWise